Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas

[1] Ferner RE(2007)Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective Lancet Neurol 6 340-351

[2] Nguyen R(2011)Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits J Pediatr 159 652-655.e652

[3] Kluwe L(1993)The neurofibromatosis type 1 gene Annu Rev Neurosci 16 183-205

[4] Fuensterer C(2007)AZD6244 (ARRY-142886), a potent inhibitor of mitogen activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Mol Cancer Ther 6 2209-2219

[5] Kentsch M(2013)KRAS mutation: should we test for it, and does it matter? J Clin Oncol 31 1112-1121

[6] Friedrich RE(2015)Biology of advanced uveal melanoma and next steps for clinical therapeutics Pigment Cell Melanoma Res 28 135-147

[7] Mautner VF(2007)Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen Clin Cancer Res 13 1576-1583

[8] Viskochil D(2016)activated protein kinase kinase 1/2 inhibitor N Engl J Med 375 2550-2560

[9] White R(2020)Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas N Engl J Med 382 1430-1442

[10] Cawthon R(2018)Selumetinib in children with inoperable plexiform neurofibromas Br J Clin Pharmacol 84 52-63

[1] Ferner RE(2007)Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective Lancet Neurol 6 340-351

[2] Nguyen R(2011)Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits J Pediatr 159 652-655.e652

[3] Kluwe L(1993)The neurofibromatosis type 1 gene Annu Rev Neurosci 16 183-205

[4] Fuensterer C(2007)AZD6244 (ARRY-142886), a potent inhibitor of mitogen activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Mol Cancer Ther 6 2209-2219

[5] Kentsch M(2013)KRAS mutation: should we test for it, and does it matter? J Clin Oncol 31 1112-1121

[6] Friedrich RE(2015)Biology of advanced uveal melanoma and next steps for clinical therapeutics Pigment Cell Melanoma Res 28 135-147

[7] Mautner VF(2007)Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen Clin Cancer Res 13 1576-1583

[8] Viskochil D(2016)activated protein kinase kinase 1/2 inhibitor N Engl J Med 375 2550-2560

[9] White R(2020)Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas N Engl J Med 382 1430-1442

[10] Cawthon R(2018)Selumetinib in children with inoperable plexiform neurofibromas Br J Clin Pharmacol 84 52-63